Homologous and Heterologous Vaccine Boost Strategies for Humoral and Cellular Immunologic Coverage of the SARS-CoV-2 Omicron Variant

This article has been Reviewed by the following groups

Read the full article See related articles

Discuss this preprint

Start a discussion What are Sciety discussions?

Abstract

The rapid spread of the highly mutated SARS-CoV-2 Omicron variant has raised substantial concerns about the protective efficacy of currently available vaccines. We assessed Omicron-specific humoral and cellular immune responses in 65 individuals who were vaccinated with two immunizations of BNT162b2 and were boosted after at least 6 months with either Ad26.COV2.S (Johnson & Johnson; N=41) or BNT162b2 (Pfizer; N=24) (Table S1).

Article activity feed

  1. SciScore for 10.1101/2021.12.02.21267198: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    EthicsIRB: The BIDMC institutional review board approved this study (2020P000361).
    Consent: All participants provided informed consent.
    Sex as a biological variablenot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Cell Line Authenticationnot detected.

    Table 2: Resources

    Antibodies
    SentencesResources
    Enzyme-linked immunosorbent assay (ELISA): SARS-CoV-2 spike receptor-binding domain (RBD)-specific binding antibodies in serum were assessed by ELISA as described previously.6,7 96-well plates were coated with 2 μg/mL of SARS-CoV-2 WA1/2020, B.1.617.2 (delta), and B.1.351 (beta) RBD protein in 1× Dulbecco phosphate-buffered saline (DPBS) and incubated at 4 °C overnight.
    B.1.351
    suggested: None
    The plates were again washed 3 times and 50 μL of SULFO-Tagged anti-Human IgG detection antibody diluted to 1x in Diluent 100 was added to each well and incubated shaking at 700 rpm at room temperature for at least 1 h.
    anti-Human IgG
    suggested: (RevMAb Biosciences Cat# 31-1019-MK, RRID:AB_2783627)
    6 106 peripheral blood mononuclear cells well were re-suspended in 100 µL of R10 media supplemented with CD49d monoclonal antibody (1 µg/mL) and CD28 monoclonal antibody (1 µg/mL).
    CD49d
    suggested: (BD Biosciences Cat# 347690, RRID:AB_647457)
    CD28
    suggested: None
    The next day, the cells were washed twice with DPBS, stained with aqua live/dead dye for 10 mins and then stained with predetermined titers of monoclonal antibodies against CD279 (clone EH12.1, BB700), CD4 (clone L200, BV711), CD27 (clone M-T271, BUV563), CD8 (clone SK1, BUV805), CD45RA (clone 5H9, APC H7) for 30 min.
    CD279
    suggested: (BD Biosciences Cat# 566460, RRID:AB_2744348)
    CD4
    suggested: None
    CD8
    suggested: (Abcam Cat# ab34397, RRID:AB_2291359)
    CD45RA
    suggested: None
    Cells were washed twice with 1X Perm Wash buffer (BD Perm/WashTM Buffer 10X in the CytoFix/CytoPerm Fixation/ Permeabilization kit diluted with MilliQ water and passed through 0.22µm filter) and stained with intracellularly with monoclonal antibodies against IFN-γ (clone B27; BUV395), and CD3 (clone SP34.2, Alexa 700), for 30 min.
    IFN-γ
    suggested: (BD Biosciences Cat# 563563, RRID:AB_2738277)
    RBD-specific B cell staining: PBMCs were stained with Aqua live/dead dye for 20 min, washed with 2% FBS/DPBS buffer, and cells were suspended in 2% FBS/DPBS buffer with Fc Block (BD) for 10 min, followed by staining with monoclonal antibodies against CD45 (clone HI30, BV786), CD3 (clone UCHT1, APC-R700), CD16 (clone 3G8, BUV496), CD14 (clone M5E2, BV605), CD19 (clone SJ25C, BUV615), CD20 (clone 2H7, PE-Cy5), IgM (clone G20-127, BUV395), IgD (clone IA6-2, PE), CD95 (clone DX2, BV711), CD27 (clone M-T271, BUV563), CD21 (clone B-ly4, PE-CF594), CD38 (clone HB7, BUV805), CD71 (clone M-A712, BV750) and staining with SARS-CoV-2 antigens including biotinylated SARS-CoV-2 (WA1/2020) RBD proteins (Sino Biological), SARS-CoV-2 (WA1/2020) RBD proteins (Sino Biological) labeled with FITC, at 4 °C for 30 min.
    CD45
    suggested: (Nanostring Cat# 121300104, RRID:AB_2893077)
    CD3
    suggested: (BD Biosciences Cat# 565119, RRID:AB_2744385)
    CD16
    suggested: (BD Biosciences Cat# 751323, RRID:AB_2875332)
    CD14
    suggested: (BD Biosciences Cat# 564054, RRID:AB_2687593)
    CD19
    suggested: (Agilent Cat# TC67401, RRID:AB_579635)
    CD20
    suggested: (BD Biosciences Cat# 740204, RRID:AB_2739954)
    PE-Cy5), IgM
    suggested: (Bioss Cat# bs-0336R-PE-Cy5, RRID:AB_10893125)
    IgD
    suggested: (Thermo Fisher Scientific Cat# 24-5093-51, RRID:AB_469565)
    CD95
    suggested: (BD Biosciences Cat# 741292, RRID:AB_2870823)
    CD27
    suggested: (BD Biosciences Cat# 751679, RRID:AB_2875665)
    CD21
    suggested: (BD Biosciences Cat# 748726, RRID:AB_2873130)
    CD38
    suggested: (BD Biosciences Cat# 742074, RRID:AB_2871359)
    CD71
    suggested: (BD Biosciences Cat# 746857, RRID:AB_2871661)
    Experimental Models: Cell Lines
    SentencesResources
    Pseudovirus neutralizing antibody assay: The SARS-CoV-2 pseudoviruses expressing a luciferase reporter gene were used to measure pseudovirus neutralizing antibodies as described previously.6,7 In brief, the packaging construct psPAX2 (AIDS Resource and Reagent Program), luciferase reporter plasmid pLenti-CMV Puro-Luc (Addgene) and spike protein expressing pcDNA3.1-SARS-CoV-2 SΔCT were co-transfected into HEK293T cells (ATCC CRL_3216) with lipofectamine 2000 (ThermoFisher Scientific).
    HEK293T
    suggested: ATCC Cat# CRL-3216, RRID:CVCL_0063)
    The mixture was incubated at 37 °C for 1 h before adding to HEK293T-hACE2 cells.
    HEK293T-hACE2
    suggested: RRID:CVCL_A7UK)
    Recombinant DNA
    SentencesResources
    Pseudovirus neutralizing antibody assay: The SARS-CoV-2 pseudoviruses expressing a luciferase reporter gene were used to measure pseudovirus neutralizing antibodies as described previously.6,7 In brief, the packaging construct psPAX2 (AIDS Resource and Reagent Program), luciferase reporter plasmid pLenti-CMV Puro-Luc (Addgene) and spike protein expressing pcDNA3.1-SARS-CoV-2 SΔCT were co-transfected into HEK293T cells (ATCC CRL_3216) with lipofectamine 2000 (ThermoFisher Scientific).
    psPAX2
    suggested: RRID:Addgene_12260)
    pLenti-CMV Puro-Luc
    suggested: None
    pcDNA3.1-SARS-CoV-2
    suggested: None
    Software and Algorithms
    SentencesResources
    Fixed cells were transferred to 96-well round bottom plate and analyzed by BD FACSymphony™ system.
    BD FACSymphony™
    suggested: None
    Subsequent analyses were performed using FlowJo software (BD Bioscience, v.9.9.6).
    FlowJo
    suggested: (FlowJo, RRID:SCR_008520)
    Statistical analysis: Descriptive statistics were calculated using GraphPad Prism 8.4.3, (GraphPad Software, San Diego, California).
    GraphPad Prism
    suggested: (GraphPad Prism, RRID:SCR_002798)
    GraphPad
    suggested: (GraphPad Prism, RRID:SCR_002798)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


    Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

    Results from TrialIdentifier: We found the following clinical trial numbers in your paper:

    IdentifierStatusTitle
    NCT04999111RecruitingA Study of Ad26.COV2.S Administered as Booster Vaccination i…


    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


    Results from JetFighter: We did not find any issues relating to colormaps.


    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    Results from scite Reference Check: We found no unreliable references.


    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.